Table 2.
Characteristics of participants with MAFLD and subtypes of MAFLD.
| Whole Sample | MAFLD | MAFLD1 | MAFLD3 | |
|---|---|---|---|---|
| N | 54 | 41(75%) | 41(75%) | 15(28%) |
| Age | 53.57 (10.21) | 52.72 (11.18) | 52.72 (11.18) | 56.47 (8.18) |
| Sex | ||||
| Female | 30 (56%) | 19 (46%) | 19 (46%) | 6 (40%) |
| Male | 24 (44%) | 22 (54%) | 22 (54%) | 9 (60%) |
| SBP (mmHg) | 130.37 (11.93) | 131.95 (12.44) | 131.95 (12.44) | 134.00 (12.85) |
| DBP (mmHg) | 82.22 (8.22) | 82.93 (8.51) | 82.93 (8.51) | 82.00 (10.99) |
| Weight (kg) | 87.19 (16.09) | 90.51 (14.61) | 90.51 (14.61) | 95.94 (16.94) |
| BMI (kg/m2) | 32.00 (5.14) | 32.82 (4.96) | 32.82 (4.96) | 34.08 (5.94) |
| TGL (mmol/L) | 1.74 (1.01) | 1.78 (0.96) | 1.78 (0.96) | 1.70 (0.76) |
| Chol-T (mmol/L) | 5.36 (1.01) | 5.21 (0.94) | 5.21 (0.94) | 4.95 (0.87) |
| HDL-C (mmol/L) | 1.15 (0.29) | 1.14 (0.30) | 1.14 (0.30) | 1.12 (0.22) |
| LDL-C (mmol/L) | 3.48 (0.61) | 3.22 (0.48) | 3.22 (0.48) | 3.37 (0.42) |
| RC (mmol/L) | 0.80 (0.46) | 0.82 (0.44) | 0.82 (0.44) | 0.78 (0.35) |
| Glucose (mmol/L) | 5.88 (1.57) | 6.03 (1.68) | 6.03 (1.68) | 7.13 (2.33) |
| ALT (μkat/L) | 0.54 (0.28) | 0.59 (0.30) | 0.59 (0.30) | 0.59 (0.30) |
| Homa-IR | 3.83 (2.34) | 4.38 (2.37) | 4.38 (2.37) | 5.22 (2.12) |
| Insulin (pmol/L) | 102.9 (66.21) | 116.59 (68.98) | 116.59 (68.98) | 125.71 (78.78) |
| Waist (cm) | 101.75 (11.84) | 104.73 (10.75) | 104.73 (10.75) | 107.90 (10.54) |
| WHR (cm) | 0.94 (0.09) | 0.96 (0.09) | 0.96 (0.09) | 0.98 (0.10) |
| Smoke | ||||
| Never/Former | 49 (91%) | 37 (90%) | 37 (90%) | 14 (93%) |
| Current | 5 (9%) | 4 (10%) | 4 (10%) | 1 (7%) |
| Diabetes | ||||
| No | 38 (70%) | 26 (63%) | 26 (63%) | 15 (100%) |
| Yes | 16 (30%) | 15 (37%) | 15 (37%) | 10 (67%) |
| Hyperlipidemia | ||||
| No | 33 (61%) | 26 (63%) | 26 (63%) | 5 (33%) |
| Yes | 21 (39%) | 15 (37%) | 15 (37%) | 7 (47%) |
| Hypertension | ||||
| No | 27 (50%) | 21 (51%) | 21 (51%) | 7 (47%) |
| Yes | 27 (50%) | 20 (49%) | 20 (49%) | 8 (53%) |
MAFLD: Metabolic-Associated Fatty Liver Disease: MAFLD1; presence of hepatic steatosis in overweight/obese subjects; MAFLD3: presence of hepatic steatosis and type 2 diabetes mellitus; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; BMI: Body Max Index; TGL: Triglycerides; Chol-T: Total Cholesterol; HDL-C: High-Density Lipoprotein; LDL-C: Low-Density Lipoprotein; RC: Remnant Cholesterol; ALT: Alanine Amino Transferase; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; WHR: Waist to Hip Ratio.